Ozanimod in relapsing forms of multiple sclerosis: a profile of its use

<p><b>Declarations</b></p><p><b><br></b></p> <p><b>Funding</b> The preparation of this review was not supported by any external funding.</p><p><br></p> <p><b>Authorship and conflicts of interest</b> M. Shirley is a salaried employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.</p><p><br></p> <p><b>Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability</b> Not applicable.</p><p><br></p><p>Additional information about this Adis Drug Review can be found <b><a href="http://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews">here</a></b><br></p><p><br></p><p>Abstract</p><p></p><p>Ozanimod (Zeposia®), a sphingosine 1-phosphate (S1P) receptor modulator with high selectivity for S1P receptor subtypes 1 and 5 (S1P1 and S1P5), represents another oral disease-modifying therapy option for the treatment of relapsing forms of multiple sclerosis (MS) in adults. In two randomised, double-blind, phase 3 clinical trials, once-daily oral ozanimod 0.92 mg significantly reduced annualised relapse rates and MRI lesion accumulation compared with once-weekly intramuscular interferon β-1a 30 µg. Furthermore, an ongoing open-label extension study provides evidence that the therapeutic effects of ozanimod are sustained in the longer term. Ozanimod is generally well tolerated. The once-daily oral administration provides a convenient dosing regimen, and the high selectivity for S1P1 and S1P5 receptors has the potential to improve safety by reducing potential off-target effects.<br></p><p><br></p><p></p><p><b>©</b> Springer Nature Switzerland AG 2020<b></b></p><p><br></p>